Data:
- MolecularFormula
- C42H83NO3
- PercentComposition
- C77.59%,H12.87%,N2.15%,O7.38%
- Purity
- >99%
- StABIlity
- 1Years
- Storage
- -20°C
- CASNumber
- 102917-80-6
CASRegistryNumberisaRegisteredTrademarkoftheAmericanChemicalSociety - MolecularWeight
- 650.113
- ExactMass
- 649.637
- Synonyms
- N-(tetracosanoyl)-sphingosineN-(tetracosanoyl)-sphing-4-enineCER(NS)CER2(C24)
AvantiPolarLipids公司是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品,由于其产品的高纯度而享誉全球。40年来,AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大,其纯度之高也是无人能及。 AvantiPolarLipids,Inc.,hasalonghistoryof50yearscreatingthehighestpuritylipidsavailable.Ourpassionforhighqualityanduniqueproductsisonlyexceededbyourexcellentreputationinthemarketplace. Althoughweareknownforourlipids,weareMorethanLipids.Weoffersolutionsfortheentireproductcycle…ResearchtoCommercialization. AvantiPolarLipids公司的主要产品和服务包括:(1)ResearchProductsHighestPurityLipidReagents(2)cGMPManufacturingAPI&ContractManufacturing(3)AdjuvantsImmunotherapy&VaccineDevelopment(4)AnalyticalServicesLipidAnalysis(5)LipidomicsMassSpecStandards,Antibodies&LipidToolbox(6)Formulationsliposomes&Nanoparticles(7)EquipmentLiposomeProductionTools(8)CustomServicesSynthesis&Beyond
AvantiPolarLipids是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品,由于其产品的高纯度而享誉全球。40年来,AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大,其纯度之高也是无人能及。
AvantiPolarLipidsInc,是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至百公斤级的磷脂类和甾体类中间体和试剂。主要产品Naturalsphingolipids天然鞘脂类Naturalphospholipids天然磷脂类Naturallipidsbyextraction天然提取脂类Referencestandards相关标准品Syntheticsphingolipids合成鞘脂类--Sphingosines&S-1-P鞘氨醇和鞘氨醇-1-磷酸盐--Ceramides神经酰胺--Sphingomyelins鞘磷脂--Sphingosine&ceramidederivatives鞘氨醇及神经酰胺衍生物--Sphinganine&derivatives鞘氨醇及其衍生物--C17sphingolipids十七碳鞘脂类--C20sphingolipids二十碳鞘脂类--Phytosphingosine&derivatives植物鞘氨醇及其衍生物Syntheticlipids&phospholipids合成脂质与磷脂--PC卵磷脂--PA磷脂酸--PE脑磷脂--PG磷脂酰甘油--PS磷脂酰丝氨酸--PI,PIP2&PIP3磷脂酰肌醇,磷脂酰肌醇-4,5-二磷酸,磷脂酰-3,4,5-三磷酸--CA胆酸--LysoPC溶源性卵磷脂--LysoPA溶源性磷脂酸--LysoPAAnalogues溶源性磷脂酸类似物--Lysobio-PA溶源性双磷脂酸--LysoPE,PG&PS溶源性脑磷脂,磷脂酰甘油和磷脂酰丝氨酸--AlkylPC烷基卵磷脂--Diether&Diphytanoyletherlipids二醚与二植烷醚脂质--PAF血小板活化因子--AcylPAFAnalog酰化血小板活化因子类似物--Brominatedphosphocholines溴代胆碱磷酸--Alkylphosphatederivatives烷基磷酸盐衍生物--Plasmalogen缩醛磷脂--Functionalizedlipids功能性脂类--Biotinylatedlipids生物素酰化脂质--Bioactivelipids生物活性脂类Syntheticphospholipids合成磷酸--AcylcoenzymeA乙酰辅酶A--Metabolicintermediates代谢中间产物--Adhesivelipid粘合脂质--pHsensitivelipids酸度计用脂质Transfectionreagents转染试剂Sterolderivatives甾酮衍生物Lipidblends混合脂质Glycosylatedphospholipids糖化磷脂Fluorinatedphospholipids氟化磷脂Chelators螯合剂Pre-mixedlipidsforbicelleformation构型分析用预混合脂质Diacylglycerols&analogues甘油二酯与类似物Deuteriumlabeledlipids氘标记脂质C13PC碳-13标记卵磷脂DoxylPC自旋标记卵磷脂TempoPCTempo(4-氧-4-羟-四甲基呱啶氮氧自由基)标记卵磷脂Fluoresecentsphingolipids荧光标记鞘脂类--Omegalabeled欧米加标记物--Fattyacidlabeled脂肪酸标记物Fluoresecentcholesterol荧光标记胆固醇Fluoresecentphospholipids荧光标记磷脂--Fattyacidlabeled脂肪酸标记物--Headgrouplabeled首基标记物Polymerizablelipids聚合脂质Poly(Ethyleneglycol)-lipidconjugates共轭聚脂质FunctionalizedPEGlipids功能PEG脂质Analyticalservices分析服务Drugdeliveryproduct药物运送载体Bulklipidsforpharmaceuticalproduction工业级脂质Equipment设备
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
果糖胺是血浆中的蛋白质与葡萄糖非酶糖化过程中形成的高分子酮胺结构类似果糖胺的物质,它的浓度与血糖水平成正相关,并相对保持稳定。它的测定却不受血糖的影响。由于血浆蛋白的半衰期为17~20天,故果糖胺可以反映糖尿病患者检测前1~3周内的平均血糖水平。从一定程度上弥补了糖化血红蛋白不能反映较短时期内血糖浓度变化的不足。果糖胺的测定快速而价廉(化学法),是评价糖尿病控制情况的一个良好指标,尤其是对血糖波动较大的脆性糖尿病及妊娠糖尿病,了解其平均血糖水平有实际意义。但果糖胺不受每次进食的影响,所以不能用来直接指导每日胰岛素及口服降糖药的用量。血清果糖胺正常值为1.64~2.64mmol/L,血浆中果糖胺较血清低0.3mmol/L。
【认领须知】
1、认领翻译的战友请跟帖注明“认领本文翻译,48小时内未完成,请其他战友认领!”
2、请根据自己专业背景选择认领,如使用翻译软件翻译,被发现者扣分1-2分
3、经常认领而不能及时提供优质稿件者将被列入黑名单,取消认领资格,请大家注意!
4、翻译时请参照版规:点击查看互
5、在首位认领战友未超过规定时间的其他任何认领属违规认领,将不会给予丁当或加分!
6、翻译完成后加分(或丁当)的时限为三日,请耐心等待,若超过时限未加者可进行申诉:点击进入
7、本文题目仅供译者参考,篇幅较长者可申请适当延时
8、翻译前请查一下有无重复帖
9、为保证翻译质量,每人每天最多只能认领两篇
10、链接:http://www.ascopost.com/News/57763
ICML2017:PhaseIIIbMAGNIFYStudyofLenalidomideandRituximabCombinationinRelapsed/RefractoryFollicularandMarginalZoneLymphoma
AninterimanalysisofMAGNIFY,aphaseIIIb,randomized,open-label,multicenterstudyoftheR2combinationregimen(lenalidomide[Revlimid]plusrituximab[Rituxan])inpatientswithrelapsedorrefractorymarginalzonelymphoma,waspresentedattheInternationalConferenceonMalignantLymphoma(ICML)inLugano,Switzerland.ThisanalysisexpandedupondatapresentedearlierinthemonthattheASCOAnnualMeeting(Abstract7502).
TheMAGNIFYstudycontinuestoevaluatetheclinicalactivityof12cyclesofR2combinationtherapyfollowedbyrandomizationtoeither18cyclesofR2maintenanceor18cyclesofrituximabmonotherapy,inpatientswithrelapsedorrefractoryfollicularlymphoma,marginalzonelymphoma,ormantlecelllymphoma.Approximately500patientsareplannedtobeenrolledinthestudy.
Theprimaryendpointisprogression-freesurvival.Secondaryendpointsincludeoverallsurvival,overallresponserate,completeresponse,improvementofresponse,durationofresponse,durationofcompleteresponse,timetonextlymphomatreatment,timetohistologictransformation,safety,andexploratoryquality-of-lifemeasures.EnrollmentintheMAGNIFYstudyisongoing.
ASCOData
AttheASCOAnnualMeeting,interimdatawerepresentedfromananalysisofasubsetofpatientsfromtheMAGNIFYstudywithrelapsedorrefractoryfollicularlymphoma(n=160)withearly-relapse(n=52)anddouble-refractory(n=50)disease.
AttheJanuary9,2017,datacutoff,the1-yearprogression-freesurvivalforallfollicularlymphomapatientswas70%,with65%fordouble-refractorypatientsand49%forearly-relapsepatients.Additionally,evaluablefollicularlymphomapatients(n=128)hadanoverallresponserateof66%withacompleteresponse/completeresponse–unconfirmedrateof38%.Fordouble-refractorypatients(n=42),overallresponseratewas45%withacompleteresponse/completeresponse–unconfirmedrateof21%andforearly-relapsepatients(n=43),overallresponseratewas47%withacompleteresponse/completeresponse–unconfirmedrateof21%.Mediandurationofresponsewasnotmetatamedianfollow-upof10.2months.
Themostcommongrade3or4adverseeventsobservedinthestudyforallfollicularlymphoma,double-refractory,andearly-relapsepatients,respectively,wereneutropenia(29%,42%,37%),fatigue(6%,4%,8%),leukopenia(5%,8%,10%),thrombocytopenia(4%,8%,4%),andlymphopenia(3%,6%,4%).
ICMLData
DatapresentedatICMLinaseparateanalysisfocusedonpatientswithmarginalzonelymphoma(n=38),includingnodalmarginalzonelymphoma(n=18),splenicmarginalzonelymphoma(n=10),andmucosa-associatedlymphoidtissuelymphoma(n=10).
Atamedianfollow-upof13.8monthsfrominitiationoftherapywiththeR2combination,evaluablepatientswithmarginalzonelymphoma(n=32)achievedanoverallresponserateof66%withacompleteresponse/completeresponse–unconfirmedrateof44%.Evaluablenodalmarginalzonelymphomapatients(n=14)hadanoverallresponserateof57%withacompleteresponse/completeresponse–unconfirmedrateof57%.Evaluablesplenicmarginalzonelymphomapatients(n=8)hadanoverallresponserateof63%withacompleteresponserateof25%;andevaluablemucosa-associatedlymphoidtissuelymphomapatients(n=10)hadanoverallresponserateof80%withacompleteresponse/completeresponse–unconfirmedrateof40%.Mediandurationofresponsewasnotreachedforanygroup.
Themostcommongrade3or4adverseeventsobservedinpatientswithmarginalzonelymphomawereneutropenia(32%),thrombocytopenia(16%),andleukopenia(11%).
“Thechemotherapy-freecombinationoflenalidomideandrituximab,withcomplementarymechanismsofactionthatarethoughttoenhanceantibodydependentcellularcytotoxicity,continuestoshowencouragingactivityandatolerablesafetyprofileinindolentlymphomas,andparticularlyindifficult-to-treatpatientsubsets,”saidDavidJ.Andorsky,MD,co–principalinvestigatorofthestudyandmedicaloncologistattheRockyMountainCancerCentersinBoulder,Colorado.“Theseresultsinpatientswhohadfailedmultipletherapiesorrelapsedearly,aswellastheactivityinmarginalzonepatientsmeritfurtherstudyinthisareaofindolentlymphoma.”
AboutMAGNIFY
MAGNIFYisaphaseIIIb,multicenter,open-labelstudyofpatientswithgrades1–3bortransformedfollicularlymphoma,marginalzonelymphoma,ormantlecelllymphomawhoreceivedatleast1priortherapyandhadstageI–IV,measurabledisease.Approximately500patientsareplannedforenrollmentin12cyclesofR2induction,withaprojected314patientswithatleaststablediseaseafterinductionrandomized(1:1)to2maintenancearms.
Inductionincludesorallenalidomideat20mg/d,days1–21per28-daycycle(d1–21/28)plusintravenousrituximabat375mg/m2,days1,8,15,and22ofcycle1andday1ofcycles3,5,7,9,and11(28-daycycles).Patientsarethenrandomizedtomaintenancelenalidomideat10mg/d,days1to21/28,cycles13to30,plusrituximabat375mg/m2,day1ofcycles13,15,17,19,21,23,25,27,and29(R2,armA),orrituximabalone(sameschedule,armB).PatientsreceivingR2maintenanceafter18cyclesmaycontinuemaintenancelenalidomidemonotherapyat10mg/d,days1–21/28(perpatientand/orinvestigatordiscretion),untildiseaseprogressionastolerated.Patientswillbefollowedfor≥5yearsafterthelastpatientinitiatesinductiontherapy.
如题,之前买的sigma的粉末,太贵。加培养基又不方便
名称:氨氧基乙酸盐;羧甲氧基胺半盐酸盐;
分子式:C2H5NO3·0.5HCl
分子质量:109.30
熔点:156℃
【认领须知】
1、认领翻译的战友请跟帖注明“认领本文翻译,48小时内未完成,请其他战友认领!”
2、请根据自己专业背景选择认领,如使用翻译软件翻译,被发现者扣分1-2分
3、经常认领而不能及时提供优质稿件者将被列入黑名单,取消认领资格,请大家注意!
4、翻译时请参照版规:点击查看
5、在首位认领战友未超过规定时间的其他任何认领属违规认领,将不会给予丁当或加分!
6、翻译完成后加分(或丁当)的时限为三日,请耐心等待,若超过时限未加者可进行申诉:点击进入
7、本文题目仅供译者参考,篇幅较长者可申请适当延时
8、翻译前请查一下有无重复帖
9、为保证翻译质量,每人每天最多只能认领两篇
10、链接:http://www.ascopost.com/News/48387
FDAApprovesLenalidomideasMaintenanceTherapyforPatientsWithMultipleMyelomaFollowingAutologousStemCellTransplant
OnFebruary22,theU.S.FoodandDrugAdmiNISTration(FDA)expandedtheexistingindicationforlenalidomide(Revlimid)10mgcapsulestoincludeuseforpatientswithmultiplemyelomaasmaintenancetherapyfollowingautologoushematopoieticstemcelltransplant.TheexpandedindicationmakeslenalidomidethefirstandonlytreatmenttoreceiveFDAapprovalformaintenanceusefollowingautologoushematopoieticstemcelltransplant.
“Autologousstemcelltransplantafterinductiontherapyispartofthecontinuumofcarefortransplant-eligIBLe[patientswith]multiplemyeloma.However,mostpatientswillstillseetheirdiseaserecurorprogressafterthistreatment,”saidPhilipMcCarthy,MD,Director,BloodandMarrowTransplantCenter,DepartmentofMedicineatRoswellParkCancerInstitute.“Lenalidomidemaintenancetherapy,whichhasbeenshowntoincreaseprogression-freesurvivalfollowingautologousstemcelltransplantinclinicaltrials,canbeconsideredastandardofcareforthesepatients.”
ClinicalTrialFindings
Theapprovalwasbasedontwolargestudies—CALGB100104andIFM2005-02—includingmorethan1,000patientscomparinglenalidomidemaintenancetherapygivenuntildiseaseprogressionorunacceptabletoxicityafterautologoushematopoieticstemcelltransplantvsnomaintenance.Inbothstudies,theprimaryefficacyendpointwasprogression-freesurvival.
Inthemostcurrentprogression-freesurvivalanalysis,Study1(CALGB100104)demonstratedamedianprogression-freesurvivalof5.7years(95%confidenceinterval[CI]=4.4–notestimable)vs1.9years(95%CI=1.6–2.5)fornomaintenance,adifferenceof3.8years(hazardratio[HR]=0.38;95%CI=0.28–0.50).
Study2(IFM2005-02)alsoshowedabenefitwithamedianprogression-freesurvivalof3.9years(95%CI=3.3–4.7)vs2years(95%CI=1.8–2.3)fornomaintenance,adifferenceof1.9years(HR=0.53;95%CI=0.44–0.64).
Individualstudieswerenotpoweredforanoverallsurvivalendpoint.
AdescriptiveanalysisshowedthemedianoverallsurvivalinStudy1was9.3years(95%CI=8.5–notestimable)forpatientswhoreceivedlenalidomidevs7years(95%CI=5.9–8.6)fornomaintenance(HR=0.59;95%CI=0.4–0.78).InStudy2,medianoverallsurvivalwas8.8years(95%CI=7.4–notestimable)forpatientswhoreceivedlenalidomidevs7.3years(95%CI=6.7–9.0)fornomaintenance(HR=0.90;95%CI=0.72–1.13).
AdverseEvents
Themostfrequentlyreportedadversereactionsin≥20%(lenalidomidearm)acrossbothmaintenancestudies(Study1,Study2respectively)wereneutropenia(79%,61%);thrombocytopenia(72%,24%);leukopenia(23%,32%);anemia(21%,9%);upperrespiratorytractinfection(27%,11%);bronchitis(5%,47%);nasopharyngitis(2%,35%);cough(10%,27%);gastroenteritis(0%,23%);diarrhea(55%,39%);rash(32%,8%);fatigue(23%,11%);asthenia(0%,30%);musclespasm(0%,33%);andpyrexia(8%,21%).ThemostfrequentlyreportedGrade3or4reactions(morethan20%inthelenalidomidearm)includedneutropenia,thrombocytopenia,andleukopenia.
Thefrequenciesofonsetofadversereactionsweregenerallyhighestinthefirst6monthsoftreatmentandthenthefrequenciesdecreasedovertimeorremainedstablethroughouttreatment.
Inpatientsreceivinglenalidomidemaintenancetherapy,hematologicsecondprimarymalignanciesoccurredin7.5%ofpatientscomparedto3.3%inpatientsreceivingplacebo.Theincidenceofhematologicplussolidtumor(excludingsquamouscellcarcinomaandbasalcellcarcinoma)secondprimarymalignancieswas14.9%,comparedto8.8%inpatientsreceivingplacebowithamedianfollow-upof91.5months.Nonmelanomaskincancersecondprimarymalignancies,includingsquamouscellcarcinomaandbasalcellcarcinoma,occurredin3.9%ofpatientsreceivinglenalidomidemaintenance,comparedto2.6%intheplaceboarm.
暂无品牌问答